

**OPERATIONAL UPDATES
FEBRUARY 2024**

HIGHLIGHTS

- **Onco-PDO™** approved for full Insurance coverage by German Public Health Insurance
- First of such coverage for personalized oncology testing for drug resistance and drug sensitivity response.

7th February 2024: Personalized Oncology and diagnostic life sciences company **Invitrocue Limited** (**'Invitrocue'**, **'the Company'** or **'the Group'**) is pleased to provide this Management and Operational update.

GERMANY: First public Insurance approved reimbursement for ONCO-PDO™

The first German public healthcare insurance has granted full coverage for Invitrocue's Onco-PDO™ phenotypic based personalized cancer drug screening for drug resistance and drug sensitivity for specific cancer patients. This service is CE Marked, covering more than 130 approved cancer drugs including Chemotherapeutic drugs, Targeted drugs, and selected Immunotherapy drugs.

Germany has a population of around 80 million where around 72 million are covered by public health insurance. In 2023, Germany saw around 500,000 new cancer patients across all cancer types.

"The coverage from public health insurance for our Onco-PDO™ Test is a significant milestone that is not only confirming the clinical value of our Test but we should see strong positive impact to the lives of cancer patients in Germany." Said Mr. Martin D. Bach, VP Operations.

Onco-PDO™ have undergone significant scientific and clinical validation with key Oncology hospital partners globally since 2015 and have so far been adopted for use in selected Asian countries and the European Union.

Accuracy rate of Onco-PDO™ is above 90% for drug resistance (whether the patient's cancer is resistant to the drug), and 70% to 95% for drug sensitivity (whether the drug will work on the patient's cancer), depending on cancer types and stages.

Onco-PDO™ currently covers all forms of solid tumors and have been validated across more than 130 approved drugs including chemotherapeutic drugs and targeted drugs. The recommended use of Onco-PDO™ will be decided by the relevant medical professions and specialist.

ONCO-PDO™ WITH MYTRUHEALTH™ EPIGENETIC TEST

The company has recently introduced a new service that utilizes epigenetic changes through its proprietary DNA Methylation test, MyTruHealth™, to identify very early alterations associated with specific cancer risk for individuals. Additionally, cancer patients undergoing treatment interventions can also benefit from MyTruHealth™ as part of a regular screening and preventive regimen to monitor the impact of treatment on their epigenetic profile and potential side effects.



MYTRUHEALTH™ & MYTRUAGE™ DNA METHYLATION TESTS

MyTruHealth™ and MyTruAge™ DNA Methylation based tests offer advanced screening of chronic diseases including the quantification of Biological Age, Immune Age and Pace of Aging. The test is currently being sold exclusively through qualified medical clinics as part of its health screening and interventions for longevity and against selected chronic diseases.

Compared to traditional DNA Tests, which solely report on gene patterns, MyTruHealth™ examines gene activation or expression, providing a more accurate and cost-effective method to map an individual's specific genomic activities. Given that most methylation attachments are reversible through a complex process of active and passive demethylation, our test not only identifies gene expression associated with chronic diseases but also offers a means to quantify the effects of clinical interventions against specific chronic diseases in individuals.

This test is available commercially in Singapore, Germany Hong Kong, Malaysia, and Thailand. Interests are also being represented from several other markets.

END

For further information, please contact:

Martin D. Bach

VP Operations

M: +65 6460 0497

E: martind.bach@invitrocue.com

www.invitrocue.com

About Invitrocue (IVQ)

Invitrocue Limited (IVQ) is an innovative life sciences company commercializing products and services in Oncology and Pharmacology, based on ground-breaking 3D models and Humanized mice platform. Headquartered in Singapore and with operations in Australia, Hong Kong, Thailand, and Germany, Invitrocue's in-vitro Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalized clinical decisions. In addition, Invitrocue's HiMice novel technology allows for the in-vivo testing of drugs and vaccines using a stable and fully human immune response.

To learn more, please visit: www.invitrocue.com